The population of adults with repaired congenital heart disease (rCHD) is growing [21]. Surgical approaches and the timing of intervention have changed over the past few decades with better survival in infancy and a trend toward death at older age [15]. Improved survival exposes more patients to the risk of late ventricular arrhythmias (VA) contributing to morbidity and sudden cardiac death (SCD). Knowledge of the individual malformation, the type of repair, and the related VA is a prerequisite for risk stratification and therapeutic interventions.

**Type and mechanism of VA**

Although sudden death may occasionally be due to cerebral, vascular, or thromboembolic events, the majority is assumed to be arrhythmic SCD [19]. Life-threatening arrhythmias rarely occur during childhood, and a time-dependent incremental risk for VA and SCD has been observed particularly in patients with repaired tetralogy of Fallot (rTOF) [6].

Although systemic ventricular dysfunction is a dominant predictor for SCD in unselected populations of adults with CHD, two thirds of those who die suddenly or experience life-threatening VTs have a preserved cardiac function prior to the event [4, 5, 19, 24]. These data suggest that different VA mechanisms may be operative.

VAs include monomorphic ventricular tachycardia (MVT), polymorphic VT, and ventricular fibrillation. It is crucial for risk stratification and treatment to understand and identify the underlying substrate for these different VAs. VAs can occur in the absence of any surgical scar or patch material, typical for patients with left heart obstruction or atrial switch operation for simple dextro-transposition of the great arteries (d-TGA).

However, MVT in these patients is uncommon. The estimated incidence rate for MVT in an unselected group of patients after atrial switch for d-TGA was 0.5 % per year [24]. The majority of documented VAs in d-TGA patients who have received an implantable cardioverter defibrillator (ICD) were polymorphic VT or ventricular fibrillation [13].

The underlying arrhythmia mechanisms are likely to be similar to those observed in other cardiac diseases with pathologic hypertrophy, fibrosis, progressive right or left ventricular dilatation, and eventually heart failure. Hypertrophy can be due to chronic pressure overload in left heart obstructions. Progressive ventricular dysfunction usually occurs if the right ventricle (RV) serves as the systemic ventricle after atrial switch operation for d-TGA or in congenitally corrected transposition of the great arteries (ccTGA). The therapeutic options comprise treatment of residual lesions, optimal heart failure management to reduce further adverse remodeling, and ICD implantation. Specific anti-arrhythmic drugs or catheter or surgical interventions are not available.

By contrast, in the presence of surgical scar and patch material, MVTs are the most common type of observed VAs. MVT after repair of TOF can serve as a paradigm of these postoperative arrhythmias [11, 20, 26].

Indeed, more than 80 % of all treated VAs in rTOF patients who have received ICDs for primary and secondary prevention were monomorphic and fast VTs with a median heart rate of 212 bpm [14]. These fast VTs can be fatal, even in the presence of a preserved cardiac function. MVTs have also been described after ventricular septal defect (VSD) closure and repair of complex d-TGA. The latter is associated with VSD in approximately 40 % of cases, or less frequently with pulmonary outflow tract obstruction, and may provide a similar substrate for macro-reentrant VTs than those observed in rTOF.

After initial repair of TOF, RV hypertrophy may develop as a result of residual RVOT obstructions. Progressive RV dilatation and dysfunction can be the consequence of chronic pulmonary regurgitation, which is more likely if initial repair is performed through a right ventriculotomy combined with the use of large transannular patches (Fig. 1). These patients may be at risk for both polymorphic VT/ventricular fibrillation and macro-reentrant VT.

**Anatomical substrate for macro-reentrant VT**

Areas of dense fibrosis after surgical incisions, patch material, and the valve annuli form regions of conduction block that can define reentry circuit borders and create intervening anatomical isthmuses (AIs) consisting of conducting myocardium [11, 26]. After repair of TOF, four AIs related to VT have been described, whose presence is dependent on the variation of the malformation and the type of repair (Fig. 2, [26]). Isthmus 1 is bordered by the tricuspid annulus and the transversal or longitudinal surgical RV
Cardiac magnetic resonance imaging (MRI; a) and intraoperative findings (b) of a patient with repaired tetralogy of Fallot (rTOF) and residual subpulmonary stenosis without ventricular tachycardia (VT). Isthmus 3 bordered by the ventricular septal defect (VSD) patch and the PV consisting of fibrous tissue precluding its participation in VT. c Cardiac MRI of a patient with rTOF and severe PV regurgitation with RVOT dilatation and VT related to a slow-conducting anatomical isthmus 3. Intraoperative cryoaablation of isthmus 3 connecting the PV and the VSD patch (d). PA pulmonary artery, SP subpulmonary stenosis, RVOT right ventricular outflow tract, LA left atrium, LV left ventricle, PV pulmonary valve, TA tricuspid annulus, VP VSD patch.

The coincidence of unexcitable anatomical boundaries and pathological remodeling over time may explain the high incidence of late macro-reentrant VT in particular in patients with rTOF.

**Risk assessment in contemporary patients with rCHD**

Most data on risk stratification are derived from patients with rTOF. Retrospective, observational studies have identified several factors associated with VA and SCD (Table 1). Currently, primary prevention ICD implantation is considered reasonable in selected adults with TOF and multiple risk factors for SCD, such as left ventricular (LV) systolic or diastolic dysfunction, nonsustained VT, a QRS width ≥180 ms, extensive RV scarring, or inducible sustained VT at electrophysiological study [1, 17].

Risk stratification in patients after the atrial switch operation for d-TGA is even more challenging. Symptoms of arrhythmias and heart failure and documented atrial flutter or fibrillation have been identified as predictors of SCD. In addition, sustained VT and SCD are more likely in patients with additional anatomical lesions, impaired RV function, NYHA class III or greater, and a QRS duration of ≥140 ms [10]. Primary prevention ICD implantation may therefore be reasonable in patients with a systemic RV ejection fraction of <35%, particularly in the presence of additional risk factors [1, 17]. However, most of the aforementioned risk factors have only limited predictive value for an individual patient and may no longer apply to the majority of contemporary patients with rCHD.

The currently applied arterial switch operation for d-TGA disconnects the aorta and pulmonary trunk from their arterial roots and connects them to the correct ventricle. The LV serves as systemic ventricle that may prevent the occurrence of late VA.

Repair of TOF has changed from a late transventricular repair after palliative shunt operation to a combined transatrial–transpulmonary approach, now usually performed early in life. The latter approach may prevent severe RV
hypertrophy, RV and LV dysfunction, and increased intraventricular pressure and fibrosis, all factors associated with late VA and SCD. In addition, AIs 1 and 2 may also be prevented by the modern approach, whereas isthmus 3 and occasionally isthmus 4 cannot be avoided. In those patients, a positive programme electrical stimulation (PES), defined as inducibility of a sustained MVT, may remain an important tool to prove the presence of a substrate for reentrant VT. Inducibility strongly depends on the applied induction protocol often requiring three extra stimuli and occasionally isoproterenol [16]. Of interest, inducibility of the clinical VT could be achieved in all patients with rCHD referred for VT ablation if stimulation was performed from a site close to the infundibular septum [11].

A wide QRS (≥180 ms) and an increase in QRS duration have consistently been reported as important risk factors for both MVT and SCD [6]. QRS prolongation has been associated with RV dilatation and arrhythmogenesis explained by a mechanoelectrical interaction [7]. However, a prolonged QRS duration may be explained not only by global conduction delay in a dilated RV. It can also be due to morphological and functional changes restricted to the RVOT and may reflect conduction delay within AIs [25]. This is further supported by the finding that surgical pulmonary valve replacement (PVR) has been associated with a reduction in RV volume but not with a consistent reduction in QRS duration after surgery [2].

In addition, replacing the valve did not eliminate the risk for MVTs, despite postoperative improvement in RV volumes and function [9]. An empirical surgical cryoablation lesion at the time of PVR, connecting the boundaries of the AIs, has shown promising results in treating and preventing MVT and has been suggested as alternative to mapping-guided intraoperative ablation [23].

Treatment for VT

Patients with rCHD and VA may be SCD survivors or present with often highly symptomatic, fast VTs (Fig. 3). According to current guidelines, an ICD should be implanted in SCD survivors after exclusion of a reversible etiology. Of importance, 70% of the patients with rTOF who have received an ICD for primary or secondary prevention required ICD shocks to terminate the first arrhythmia [14]. Even if ATP was programmed and delivered appropriately, it failed in 81% of patients with rCHD [18]. Therefore, additional therapeutic interventions are needed.

There are no specific data available on the efficacy of antiarrhythmic drugs in the past few decades, progress has been made to determine the anatomical basis for monomorphic VT in patients with ventricular surgical scars and patch material. These substrates can be currently identified and targeted during sinus rhythm by radiofrequency catheter or surgical ablation without the need for VT induction. The review provides an update on the evolving surgical approaches, the changing VA substrates, and the potential consequences for individualized risk assessment and tailored treatment.

Keywords
Ventricular tachycardia · Repaired congenital heart disease · Tetralogy of Fallot · Catheter mapping · Radiofrequency catheter ablation
Postmortem specimens of repaired tetralogy of Fallot (rTOF; a–c), unrepaired TOF (d), and unrepaired dextro-transposition of the great arteries (e). Anterior views (a, b), right ventricular views (c–e). Anatomical isthmuses (AIs) 1–4 are indicated. Unexcitable borders are (potential) patches (ventricular septal defect patch is folded back in c), PV and TA. Schematic of AIs 1–4 in rTOF (f). PV pulmonary valve, TA tricuspid annulus, RVOT right ventricular outflow tract, VSD ventricular septal defect.

Clinical VT 260 bpm

Modified anterior view

Isthmus 1 between TP & TA

PV

Modified posterior view

Isthmus 3 between PV & VP

Length: 16.7 mm

Modified posterior view

Pace-match at site B

PV

Modified posterior view

RF line connecting PV & VP

Length: 16.7 mm

Activation time A to D = 62 ms
CV 62 ms/26 mm = 0.4 m/s

Activities map during sinus rhythm. Isthmus 3 was the only slowconducting AI (conduction velocity = 0.4 m/s) and related to VT, demonstrated by pace-mapping (pace-match of VT was obtained at site B; not shown). Connecting the PV and VP with a linear RF lesion resulted in blocking of AI 3 preventing VT re-induction and VT recurrence.
rCHD. In general, the available drugs to prevent recurrence of reentrant VT in structural heart disease have limited efficacy. Sotalol or Amiodarone may be effective in reducing appropriate ICD therapy but their use is often hampered by serious side effects leading to drug discontinuation. The feasibility of radiofrequency catheter ablation (RFCA) in patients with rCHD was reported 20 years ago, the majority performed in TOF patients with rCHD referred for RFCA or studied for risk stratification are macro-reentrant VTs with a critical reentry circuit isthmus located within anatomically defined isthmuses [11].

These AIs can be reconstructed with point-by-point electroanatomical voltage mapping during stable sinus rhythm using three-dimensional electroanatomical mapping systems (Fig. 3). Peak-to-peak bipolar electrogram amplitudes can be displayed color-coded as a voltage map and projected on a three-dimensional shell of the RV. In addition, local activation times derived from bipolar and unipolar electrograms can be displayed as an activation map. Electrograms greater than 1.5 mV are considered normal voltage. At sites with amplitudes less than 0.5 mV, high-output pacing (10 mA, 2 ms) can be performed to identify unexcitable tissue. Noncapture sites, consistent with patch material or surgical scars, serve as boundaries of AIs [11, 26].

The critical reentry circuit isthmus of each induced VT can be occasionally determined by activation and entrainment mapping for tolerated VT. However, considering the often hemodynamically unstable VTs, pace-mapping within AIs is often applied to determine whether the critical isthmus is likely located within an anatomically defined isthmus. The VT-related AI can be transected by connecting the adjoining anatomic boundaries by a linear RF lesion [26].

An alternative approach for mapping of poorly tolerated VTs has applied non-contact mapping [20]. The system, consisting of a multielectrode balloon array, allows for the simultaneous acquisition of virtual unipolar electrograms and recording of the activation sequence requiring only a single VT beat. The VT circuit and the critical VT isthmus can be displayed on the anatomic shell and the corresponding AI can be targeted by RFCA.

Demonstration of conduction block after transection of an AI is an accepted and clearly defined procedural endpoint. Accordingly, noninducibility of any VT and transection of the critical AI was defined as complete procedural success and achieved in 25 of 34 adults with VT after CHD repair. None of these patients had recurrence of a monomorphic VT during 46 ± 29 months of follow-up [11]. These data strongly support the concept that specific “arrhythmogenic” AIs are the substrate for macro-reentrant VT in rCHD that can be effectively treated by catheter ablation. Confirmed conduction block of the arrhythmogenic AI should be attempted and, if successful, may be considered curative in patients with preserved cardiac function and no competing heart failure-related VA mechanism.

### Arrhythmogenic anatomical isthmuses

The 12-lead morphology of the clinically documented or induced VT may already provide an indication of the AI being involved (Fig. 3). However, specific electroanatomical characteristics, including isthmus width and conduction velocity through an AI, may allow for direct identification of the “arrhythmogenic” AI that needs to be targeted by ablation. This information is available after the three-dimensional reconstruction of voltage and activation maps during stable sinus rhythm. In a cohort of 74 TOF patients, only electroanatomical narrow and slow-conducting AIs (calculated conduction velocity <0.5 m/s) were the substrate for all 37 documented and induced MVTs in 24 patients with preserved cardiac function (unpublished data). The inability to transect an AI may be due to the hypertrophied myocardium preventing transmural lesions. Perhaps more important, patch material or a pulmonary homograft implanted for late pulmonary valve regurgitation may cover parts of the arrhythmogenic isthmus. Occasionally, a left-sided approach from the aortic root or LV outflow tract can be successful for transecing this isthmus [12]. In patients who need to undergo re-operation, preoperative PES and electroanatomical mapping followed by preventive intraoperative ablation of

---

**Table 1** Reported risk factors for VT and/or SCD in rTOF

| Risk Factor | Definition |
|------------|------------|
| Older age at repair |  |
| Transannular patch |  |
| RV parameter (moderate to severe dysfunction, severe dilatation, LGE, akinetic region length, mass/volume ratio ≥0.3 g/ml) |  |
| Moderate to severe PVR |  |
| LV parameter (moderate to severe dysfunction, longitudinal strain, end-diastolic pressure) |  |
| History of atrial arrhythmias |  |
| (Pre)Syncope |  |
| QRS duration (≥180 ms), QRS duration increase per year |  |
| Nonsustained VT |  |
| Inducible for MVT/PVT at PES |  |
| RV right ventricle, LGE late gadolinium enhancement, PVR pulmonary valve regurgitation, LV left ventricle, VT ventricular tachycardia, MVT monomorphic ventricular tachycardia, PVT polymorphic ventricular tachycardia, PES programmed electrical stimulation, rTOF repaired tetralogy of Fallot, SCD sudden cardiac death |  |

---
potentially arrhythmogenic AIs should therefore be considered.

Conclusion
Risk stratification and treatment of complex VAs in patients with rCHD remain challenging and require a multidisciplinary approach. Progress has been made in understanding and delineating the substrate for MVT. The strong link between slow-conducting AIs and the often poorly tolerated VTs allows for RFCA without VT inducibility and (preventive) surgical ablation in those who need surgical re-interventions. Substrate identification may overcome the problem of lacking clinical arrhythmia predictors and could facilitate personalized risk stratification and tailored treatment in the contemporary population of patients with rCHD.

Corresponding address
K. Zeppenfeld, MD, PhD
Department of Cardiology, CS-P, Leiden University Medical Centre
PO Box 9600, 2300 RC Leiden, The Netherlands
K.Zeppenfeld@lumc.nl

Compliance with ethical guidelines

Conflict of interest. K. Zeppenfeld states that there are no conflicts of interest.

The accompanying manuscript does not include studies on humans or animals.

Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References
1. Baumgartner H, Bonhoeffer P, Groot NM De et al (2010) ESC Guidelines for the management of grown-up congenital heart disease. Eur Heart J 31:2915–2957 (new version 2010.)
2. Cheung EW, Wong WH, Cheung YF (2010) Meta-analysis of pulmonary valve replacement after operative repair of tetralogy of fallot. Am J Cardiol 106:552–557
3. Chowdhury UK, Sathia S, Ray R et al (2006) Histopathology of the right ventricular outflow tract and its relationship to clinical outcomes and arrhythmias in patients with tetralogy of Fallot. J Thorac Cardiovasc Surg 132:270–277
4. Diller GP, Kempny A, Lodakis E et al (2012) Left ventricular longitudinal function predicts life-threatening ventricular arrhythmia and death in adults with repaired tetralogy of fallot. Circulation 125:2440–2446
5. Gallego P, Gonzalez AE, Sanchez-Recalde A et al (2012) Incidence and predictors of sudden cardiac arrest in adults with congenital heart defects repaired before adult life. Am J Cardiol 110:109–117
6. Gatzoulis MA, Balaji S, Webber SA et al (2000) Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet 356:975–981
7. Gatzoulis MA, Till JA, Somerville J et al (1995) Mechanoelectrical interaction in tetralogy of Fallot. QRS prolongation relates to right ventricular size and predicts malignant arrhythmias and sudden death. Circulation 92:231–237
8. Gonska BD, Cao K, Raab J et al (1996) Radiofrequency catheter ablation of right ventricular tachycardia late after repair of congenital heart defects. Circulation 94:1902–1908
9. Harrild DM, Ball C, Cecchin F et al. (2009) Pulmonary valve replacement in tetralogy of Fallot: impact on survival and ventricular tachycardia. Circulation 119:445–451
10. Kammeraad JA, Van Deurzen CH, Steeram N et al (2004) Predictors of sudden cardiac death after Mustard or Senning repair for transposition of the great arteries. J Am Coll Cardiol 44:1095–1102
11. Kapel GF, Reichlin T, Wijnmaalen AP et al (2015) Re-entry using anatomically determined isthmuses: a curable ventricular tachycardia in repaired congenital heart disease. Circ Arrhythm Electrophysiol 8:102–109
12. Kapel GF, Reichlin T, Wijnmaalen AP et al (2014) Left-sided ablation of ventricular tachycardia in adults with repaired tetralogy of Fallot: a case series. Circ Arrhythm Electrophysiol 7:889–897
13. Khairy P, Harris L, Landzberg MJ et al (2008) Sudden death and defibrillators in transposition of the great arteries with intra-atrial baffles: a multicenter study. Circ Arrhythm Electrophysiol 1:250–257
14. Khairy P, Harris L, Landzberg MJ et al (2008) Implantable cardioverter-defibrillators in tetralogy of Fallot. Circulation 117:363–370
15. Khairy P, Ionescu-Ittu R, Mackie AS et al (2010) Changing mortality in congenital heart disease. J Am Coll Cardiol 56:1149–1157
16. Khairy P, Landzberg MJ, Gatzoulis MA et al (2004) Value of programmed ventricular stimulation after tetralogy of fallot repair: a multicenter study. Circulation 109:1994–2000
17. Khairy P, Van Hare GF, Balaji S et al (2014) PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease. Heart Rhythm 11:e102–e165 (developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD))
18. Kozyak Z, Groot JR De, Van Gelder IC et al (2012) Implantable cardioverter defibrillator therapy in adults with congenital heart disease: who is at risk of shocks? Circ Arrhythm Electrophysiol 5:101–110
19. Kozyak Z, Harris L, Groot JR De et al (2012) Sudden cardiac death in adult congenital heart disease. Circulation 126:1944–1954
20. Kriebel T, Saul JP, Schneider H et al (2007) Noncontact mapping and radiofrequency catheter ablation of fast and hemodynamically unstable ventricular tachycardia after surgical repair of tetralogy of Fallot. J Am Coll Cardiol 50:2162–2168
21. MARELLI AJ, Mackie AS, Ionescu-Ittu R et al (2007) Congenital heart disease in the general population: changing prevalence and age distribution. Circulation 115:163–172
22. Moore JP, Seki A, Shannon KM et al (2013) Characterization of anatomic ventricular tachycardia isthmus pathology after surgical repair of tetralogy of Fallot. Circ Arrhythm Electrophysiol 6:905–911
23. Sabate RA, Connolly HM, Warnes CA et al (2015) Ventricular arrhythmia risk stratification in patients with tetralogy of Fallot at the time of pulmonary valve replacement. Circ Arrhythm Electrophysiol 8:110–116
24. Silka MJ, Hardy BG, Menashe VD et al (1998) A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. J Am Coll Cardiol 32:245–251
25. Uebing A, Gibson DG, Babu-Narayan SV et al (2007) Right ventricular mechanics and QRS duration in patients with repaired tetralogy of Fallot: implications of infundibular disease. Circulation 116:1532–1539
26. Zeppenfeld K, Schallj MJ, Bartelings MM et al (2007) Catheter ablation of ventricular tachycardia after repair of congenital heart disease: electroanatomic identification of the critical right ventricular isthmus. Circulation 116:2241–2252